Aktienanalyse zu Alterity Therapeutics Limited (ATHE)ATHEAlterity Therapeutics Limited

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alterity Therapeutics is a good buy right now due to its recent positive FDA feedback for ATH434, which supports its Phase 3 program, and the stock's current price of $4.51 is significantly lower than the analyst price targets, indicating potential upside. The RSI is at 44.707, suggesting the stock is not overbought, and the 20-day change is +2.15%, indicating a recent positive trend. However, the main risk is the negative earnings report which caused a 4.6% drop in market price.